DelveInsight's Mismatch Repair Deficiency Market Insights report includes a comprehensive understanding of current treatment practices, mismatch repair deficiency emerging drugs, market share of ...
MSD and Eisai presented the data at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The ...
Lynch Syndrome (LS) is a common hereditary condition that greatly increases lifetime risk of colorectal, endometrial, urothelial and other ...
MedPage Today on MSN
Chemotherapy-Free Combo Improves Survival in Metastatic Colorectal Cancer
BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly ...
Across conversations on precision oncology, malignant hematology, cellular therapies, and social determinants of health (SDOH ...
The ultimate recommendation is to utilize immune checkpoint blockade in the front-line setting, even for pMMR patients. This ...
Keytruda plus Lenvima demonstrates durable 5-year survival benefit versus chemotherapy for patients with advanced endometrial carcinoma following one prior platinum-based regimen ...
Researchers from Memorial Sloan Kettering Cancer Center (MSK) presented new studies related to a range of cancer types at the ...
Ipilimumab plus nivolumab improved PFS over nivolumab alone in MSI-H/dMMR mCRC, with no new safety concerns. The combination showed higher overall response rates and a favorable safety profile ...
Market Implications: The ongoing study could significantly impact GSK’s stock performance by potentially introducing a new cancer treatment option, enhancing GSK’s oncology portfolio. Positive results ...
A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback